Scarica l'app Stockscreener
803.90
0.72%
5.73
Pre-mercato:
809.00
5.10
+0.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché REGN Giù?
Forum
Previsione
Precedente Chiudi:
$798.17
Aprire:
$802.48
Volume 24 ore:
596.94K
Relative Volume:
0.76
Capitalizzazione di mercato:
$82.77B
Reddito:
$14.92B
Utile/perdita netta:
$4.42B
Rapporto P/E:
19.59
EPS:
41.0422
Flusso di cassa netto:
$3.79B
1 W Prestazione:
+3.85%
1M Prestazione:
-3.61%
6M Prestazione:
+9.69%
1 anno Prestazione:
+34.96%
Intervallo 1D:
$791.31
$811.66
Intervallo di 1 settimana:
$771.80
$811.66
Portata 52W:
$541.00
$859.34
Regeneron Pharmaceuticals Inc Stock (REGN) Company Profile
Nome
Regeneron Pharmaceuticals Inc
Settore
Industria
Telefono
(914) 847-7000
Indirizzo
777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY
Compare REGN vs VRTX, MRNA, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
REGN
Regeneron Pharmaceuticals Inc
|
803.90 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
VRTX
Vertex Pharmaceuticals Inc
|
514.99 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
182.56 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
963.79 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
368.08 | 39.20B | 5.76B | 514.49M | 1.10B | 4.4813 |
Regeneron Pharmaceuticals Inc Stock (REGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-31 | Ripresa | Piper Sandler | Overweight |
| 2026-03-06 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | BofA Securities | Underperform → Buy |
| 2025-12-03 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2025-11-24 | Iniziato | HSBC Securities | Buy |
| 2025-11-24 | Ripresa | Truist | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-14 | Iniziato | Rothschild & Co Redburn | Buy |
| 2025-06-30 | Downgrade | Argus | Buy → Hold |
| 2025-05-30 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-05-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-05-14 | Aggiornamento | Citigroup | Neutral → Buy |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-05 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-01-16 | Downgrade | UBS | Buy → Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-09-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2024-03-12 | Iniziato | Bernstein | Outperform |
| 2024-01-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-03 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2023-08-21 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-21 | Reiterato | Oppenheimer | Perform |
| 2023-06-28 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2023-03-27 | Aggiornamento | SVB Securities | Market Perform → Outperform |
| 2023-03-24 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-03-23 | Aggiornamento | Raymond James | Underperform → Mkt Perform |
| 2023-01-30 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2023-01-20 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-10-26 | Downgrade | Raymond James | Mkt Perform → Underperform |
| 2022-10-17 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-09-09 | Aggiornamento | Jefferies | Underperform → Hold |
| 2022-09-09 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-07-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-06-06 | Iniziato | Jefferies | Underperform |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-01-05 | Downgrade | BofA Securities | Neutral → Underperform |
| 2022-01-03 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-12-15 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2021-12-09 | Ripresa | Wells Fargo | Overweight |
| 2021-12-07 | Ripresa | Cowen | Market Perform |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Ripresa | BMO Capital Markets | Outperform |
| 2021-11-05 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-06-29 | Iniziato | H.C. Wainwright | Buy |
| 2021-01-25 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-01-13 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-01-08 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-10-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2020-08-20 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-07-09 | Aggiornamento | SunTrust | Hold → Buy |
| 2020-05-26 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-04-28 | Downgrade | Citigroup | Buy → Neutral |
| 2020-04-17 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-04-08 | Iniziato | The Benchmark Company | Hold |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-02-27 | Iniziato | Barclays | Overweight |
| 2020-02-26 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2020-02-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2020-02-25 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-11 | Aggiornamento | Argus | Hold → Buy |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-16 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-12-13 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-11-12 | Iniziato | SunTrust | Hold |
| 2019-11-07 | Aggiornamento | Citigroup | Neutral → Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-09-23 | Aggiornamento | Guggenheim | Neutral → Buy |
Mostra tutto
Regeneron Pharmaceuticals Inc Borsa (REGN) Ultime notizie
State Street Corp Increases Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals stock trades near its yearly high - AD HOC NEWS
Why is Regeneron Pharmaceuticals (NASDAQ:REGN) back on investors' radar? - Kalkine Media
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Is Regeneron Stock a Bargain Below $800? - The Motley Fool
Regeneron Pharmaceuticals, Inc. $REGN Shares Acquired by Andra AP fonden - MarketBeat
Regeneron stock gains 1.67 percent as legal risk eases - AD HOC NEWS
Here’s How Much You Would Have Made Owning Regeneron Pharmaceuticals Stock In The Last 20 Years - Benzinga
Regeneron, Bayer Hit Back In Eye Med Biosimilar Clash - Law360
Regeneron Pharmaceuticals stock holds near its yearly range - AD HOC NEWS
REGN Watch: What Regeneron Pharmaceuticals's Latest Moves Mean for Healthcare Stocks Investors - Kalkine Media
Regeneron stock heads into the open after a 1.7 percent gain - AD HOC NEWS
Regeneron Investors Can't Use FCA Action To Support Suit - Law360
Regeneron Pharmaceuticals Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Regeneron stock gains as legal risk eases and dividend profile stands out - AD HOC NEWS
Regeneron Beats Investor Suit Over Medicare Drug Price Reporting - Bloomberg Government News
Regeneron stock heads into the open after a 0.4 percent gain - AD HOC NEWS
Regeneron stock gains analyst support after strong quarterly figures - AD HOC NEWS
Nykredit A S Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded by Wall Street Zen to Strong-Buy Rating - MarketBeat
Why Regeneron Pharmaceuticals (NASDAQ:REGN) Is Back in Focus? - Kalkine Media
How Investors Are Reacting To Regeneron Pharmaceuticals Stock (REGN) Trial Disclosure Lawsuits - simplywall.st
Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Is Regeneron Pharmaceuticals (REGN) Still Undervalued After The Class Action Lawsuits? - simplywall.st
Will Fianlimab-Libtayo Trial Misstatement Lawsuits Change Regeneron Pharmaceuticals' (REGN) Pipeline-Driven Narrative? - Yahoo Finance
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance
Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action - PR Newswire
Bronstein, Gewirtz & Grossman LLC Urges Regeneron Pharmaceuticals, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - lincolnjournal.com
REGN INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds - The National Law Review
REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - PR Newswire
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. Invest - The National Law Review
REGN 2-DAY DEADLINE ALERT: Regeneron Pharmaceuticals, Inc. - GlobeNewswire
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth - Yahoo Finance
Is Regeneron (NASDAQ:REGN) Entering A New Phase? - Kalkine Media
INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investo - The National Law Review
Regeneron stock dips ahead of class action deadline - ad-hoc-news.de
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron I - The National Law Review
MONDAY INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP - GlobeNewswire
Why Is Regeneron Pharmaceuticals (REGN) Facing A New Investor Lawsuit? - simplywall.st
Regeneron stock heads into the open after a 1.8 percent drop - ad-hoc-news.de
Regeneron Pharmaceuticals Inc. stock outperforms competitors despite losses on the day - MarketWatch
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces - FinancialContent
Best Biotech Stocks To Add to Your WatchlistSeptember 10th - MarketBeat
Regeneron Pharmaceuticals More Likely to Retain Eylea HD Patent, RBC Says - marketscreener.com
REGN Maintained by HSBC -- Price Target Raised to $920 - GuruFocus
Regeneron stock gains after strong Q2 2026 earnings beat - ad-hoc-news.de
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming DeadlinesREGN - PR Newswire
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE - GlobeNewswire
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. LawsuitREGN - PR Newswire
REGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Anno - The National Law Review
REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit - PR Newswire
Regeneron Pharmaceuticals Inc Azioni (REGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Regeneron Pharmaceuticals Inc Azioni (REGN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| McCourt Marion | EVP Commercial |
Sep 03 '26 |
Sale |
857.39 |
1,131 |
969,708 |
12,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Option Exercise |
719.37 |
400 |
287,748 |
1,003 |
| Guarini Kathryn | Director |
Sep 02 '26 |
Sale |
850.00 |
400 |
340,000 |
603 |
5.56%
2.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):